Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Ernstoff

Showing results (101-110 of 169) with videos related to

Pageof 17
Sort By:
Cancer|October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Scientific Reports|August 29, 2018
Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironmentShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Scientific Reports|March 16, 2019
Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironmentShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
The Journal of Molecular Diagnostics : JMD|October 25, 2017
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid TumorsJeffrey M Conroy, Sarabjot Pabla, Sean T Glenn, et al.
Pageof 17

Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
Cancer|October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 studyShailender Bhatia, Brendan Curti, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Scientific Reports|August 29, 2018
Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironmentShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Scientific Reports|March 16, 2019
Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironmentShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.
The Journal of Molecular Diagnostics : JMD|October 25, 2017
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid TumorsJeffrey M Conroy, Sarabjot Pabla, Sean T Glenn, et al.
Pageof 17